Vera Therapeutics is trading 7.14% up at $34.53, but no catalyst has been confidently identified.
- No company-specific announcement, filing, analyst action, or clinical update dated August 24, 2026, was identified.
- The latest major company update, dated August 10, highlighted TRUTAKNA’s accelerated FDA approval and upcoming Phase 3 eGFR results.
- Trading is active during the open session; volume information was not provided. The market backdrop is mixed-to-lower.